Biotech Values

[DonShimoda]

Peter, your points are well-taken. In the end, I concluded that Stanford's progress would at least validate the target. My bet is that a partnership may be possible as soon as Stanford validates CD47 in the clinic and SCTPF has IND-enabling studies in hand.